Depomed, Inc. (NASDAQ:DEPO) retreated its position after shares change of 3.79% on Thursday and it traded at $6.03. The 52-week high of the share price is -77.68% and 52-week low of the share price is 3.97%.
Khang&Khang LLP reported that a securities class action lawsuit against Depomed, Inc. (DEPO). Investors, who purchased or otherwise purchased Depomed shares from February 26, 2015 through August 7, 2017, inclusive, are encouraged to contact the Firm before October 17, 2017, the lead plaintiff motion deadline.
According to the Complaint, during the Class Period, Depomed made false and/or misleading statements, and/or failed to disclose: that the Company engaged in questionable practices in connection with the sales and marketing of its opioid products; that this conduct would likely subject Depomed to heightened legal and regulatory scrutiny; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 7, 2017, Depomed reported that it “recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” and that Depomed had also received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.”
The shares performance of DEPO was -2.74% for the last one month and 1.52% in the previous week, whereas year to date performance was calculated -66.54%. The goal of share performance is to compare managers to the interests of shareholders. Their goal is alike to employee stock-option plans, as they offer an explicit incentive for management to focus their efforts on maximizing shareholder value. When calculating in the EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at -14.90%. Investors looking further ahead will note that the Price to next year’s EPS is 46.44%.
In latest trading session, KB Home (NYSE:KBH) inched up 0.89% with 1.9 Million trading volume. KB Home (NYSE: KBH) reported that the grand opening of Mills Creek Crossing, its newest community of single-family homes located in the North Cy-Fair neighborhood of Houston. Mills Creek Crossing’s commuter-friendly location offers easy access to Beltway 8, US Route 290, and Texas State Highway 249, making it convenient to major employment centers, including the Energy Corridor, Galleria, and downtown Houston. Further, George Bush Intercontinental Airport is less than 20 miles away.
Located within the Cypress-Fairbanks Independent School District, Mills Creek Crossing is within walking distance of a brand new elementary school, Matzke Elementary, and Cypress Creek High School. Residents of Mills Creek will also enjoy its proximity to McWilliams YMCA, Champions Golf Club, and Willowbrook Mall. Nearby Matzke Park features sport fields, play equipment, walking trails, and a butterfly garden, while the exquisitely-landscaped Mandolin Gardens Park is the perfect setting for a peaceful walk or an afternoon picnic.
As part of KB Home’s unique homebuying experience, buyers at Mills Creek Crossing will have the opportunity to personalize many aspects of their new home, including lot and floor plan, exterior elevation, and interior finishes to best fit their lifestyle and budget. As with all KB homes, those offered at Mills Creek Crossing will be built to ENERGY STAR® guidelines and include WaterSense labeled faucets and fixtures, meaning they are designed to be more energy- and water-efficient than other typical new and resale homes.
As concerns shares volumes, in share Capital Company has 85.14 million outstanding shares among them 74.25 million shares have been floated in market exchange.